<![CDATA[ AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)]]>https://aidsinfo.nih.gov/e-news/archive60<![CDATA[AIDSinfo Releases Fact Sheet on Biktarvy, a New Combination Drug to Treat Certain Adults with HIV]]>https://aidsinfo.nih.gov/e-news/archive/2018/2/22On February 7, 2018, the Food and Drug Administration (FDA) approved Biktarvy, a new antiretroviral drug to treat HIV infection in adults. The three-drug (bictegravir, emtricitabine, and tenofovir alafenamide), fixed-dose combination tablet is a complete regimen for adults who have never taken HIV medicines before. Biktarvy may also provide a treatment alternative for adults on a current HIV regimen who meet specific criteria. For information on Biktarvy, including details on who can take the drug, please see the AIDSinfo Biktarvy fact sheet [en español].

Do you want to learn more about HIV medicines? Check out the AIDSinfo FDA-Approved HIV Medicines fact sheet and infographic.

 

]]>
Thu, 22 Feb 2018 00:00:00 -0500
<![CDATA[ Updates to the HHV-8 Section of the Adult and Adolescent Opportunistic Infections Guidelines]]>https://aidsinfo.nih.gov/e-news/archive/2018/2/22The Human Herpesvirus-8 (HHV-8) section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was updated on February 21, 2018. In this revision, the epidemiology of HHV-8 infection and HHV-8 related malignancies have been revised to reflect current data, and information about the newly described clinical syndrome, the KSHV inflammatory cytokine syndrome (KICS), is provided. Treatment recommendations for multicentric Castleman's disease have been updated.

 

]]>
Thu, 22 Feb 2018 00:00:00 -0500
<![CDATA[ HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Welcomes New Panel Members]]>https://aidsinfo.nih.gov/e-news/archive/2018/2/22The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (a working group of the Office of AIDS Research Council) is pleased to welcome the following new scientific members to the Panel who will begin a 4-year term starting in April 2018.

  • Curt Beckwith, MD (Brown University, Providence, RI)
  • R. Douglas Bruce, MD, MA, MS (Cornell Scott-Hill Health Center/Yale University, New Haven, CT)
  • Geetanjali Chander, MD, MPH (Johns Hopkins University, Baltimore, MD)
  • Eric Daar, MD (University of California Los Angeles, Los Angeles, CA)
  • Steven C. Johnson, MD (University of Colorado, Aurora, CO)
  • Tonia Poteat, PhD, MPH, PA-C (Johns Hopkins University, Baltimore, MD)
  • Asa Radix, MD, MPH (Callen-Lorde Community Health Center/New York University, New York, NY)
The Panel would also like to welcome Virginia Sheikh, MD, MHS, of the U.S. Food and Drug Administration (FDA) who joined the Panel in January 2018 as a representative from the FDA.

The Panel would like to express our gratitude and appreciation to the following outgoing members for the many years of dedication and contributions in the development of these guidelines:
  • Charles Hicks, MD (formerly University of California San Diego, San Diego, CA)
  • Richard Price, MD (University of California San Francisco, San Francisco, CA)
  • Adam Sherwat, MD (U.S. Food and Drug Administration, Silver Spring, MD)
  • Jeff Taylor (AIDS Treatment Activists Coalition, Palm Springs, CA)
  • Zelalam Temesgen, MD (Mayo Clinic, Rochester, MN)

 

]]>
Thu, 22 Feb 2018 00:00:00 -0500
<![CDATA[ Recent HIV News from NIH]]>https://aidsinfo.nih.gov/e-news/archive/2018/2/22
  • February 16, 2018: PHAT Life: Effective HIV Intervention for Youth in the Criminal Justice System
  • ]]>
    Thu, 22 Feb 2018 00:00:00 -0500
    <![CDATA[AIDSinfo Updates Consumer Fact Sheets on HIV Treatment]]>https://aidsinfo.nih.gov/e-news/archive/2018/2/9The updated AIDSinfo consumer fact sheets provide important information about HIV treatment. Each fact sheet includes a summary of key points and links to additional information and resources.

    View the updated fact sheets:

    Visit infoSIDA to view the fact sheets in Spanish.
     

     

    ]]>
    Fri, 9 Feb 2018 00:00:00 -0500
    <![CDATA[ Scientific/Clinical Member Nominations Are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV]]>https://aidsinfo.nih.gov/e-news/archive/2018/2/9The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in:

    • pharmacology of antiretrovirals in infants, children, and adolescents
    • clinical use of antiretrovirals in infants and children
    • care of adolescents and young adults with perinatally acquired HIV
    Individuals who served as Panel members in the past are welcome to reapply.

    Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 3-year term beginning April 2018, with potential for reappointment for an additional term.

    The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of approximately 30 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy in children and to revise the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.

    Panel members are not financially compensated for their time commitment.

    The nomination should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Angie Landenburger, AIDSinfo Guidelines Coordinator, at angie.landenburger@icf.com, no later than February 23, 2018.
     

     

    ]]>
    Fri, 9 Feb 2018 00:00:00 -0500
    <![CDATA[ FDA Approves Biktarvy (a Fixed-Dose Combination Tablet) to Treat HIV Infection]]>https://aidsinfo.nih.gov/e-news/archive/2018/2/9On February 7, 2018, the Food and Drug Administration (FDA) approved Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide), a three-drug, fixed-dose combination tablet indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in people who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

    The Biktarvy label is available on the FDA website.

     

    ]]>
    Fri, 9 Feb 2018 00:00:00 -0500
    <![CDATA[Scientific/Clinical Member Nominations Are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV]]>https://aidsinfo.nih.gov/e-news/archive/2018/1/26The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in:

    • pharmacology of antiretrovirals in infants, children, and adolescents
    • clinical use of antiretrovirals in infants and children
    • care of adolescents and young adults with perinatally acquired HIV

    Individuals who served as Panel members in the past are welcome to reapply.

    Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 3-year term beginning April 2018, with potential for reappointment for an additional term.

    The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of approximately 30 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy in children and to revise the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.

    Panel members are not financially compensated for their time commitment.

    The nomination should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Angie Landenburger, AIDSinfo Guidelines Coordinator, at angie.landenburger@icf.com, no later than February 23, 2018.

     

    ]]>
    Fri, 26 Jan 2018 00:00:00 -0500
    <![CDATA[ February 7 is National Black HIV/AIDS Awareness Day]]>https://aidsinfo.nih.gov/e-news/archive/2018/1/26According to the Centers for Disease Control and Prevention (CDC), compared with other races and ethnicities, African Americans account for a higher proportion of new HIV diagnoses, those living with HIV, and those ever diagnosed with AIDS. In 2015, African Americans accounted for 45% of HIV diagnoses, though they account for only 12% of the U.S. population.

    February 7 is National Black HIV/AIDS Awareness Day—a day set aside each year to raise awareness, promote HIV education, testing, community involvement, and treatment in black communities. To learn more about this annual observance, visit our National Black HIV/AIDS Awareness Day webpage [en español].

     

    ]]>
    Fri, 26 Jan 2018 00:00:00 -0500
    <![CDATA[ Recent HIV News from NIAID]]>https://aidsinfo.nih.gov/e-news/archive/2018/1/26
  • January 24, 2018: NIH Begins Large HIV Treatment Study in Pregnant Women
  • January 24, 2018: Study Links Gut-Homing Protein Levels with HIV Infection Risk, Disease Progression
  • January 24, 2018: 15 Years Later, PEPFAR Continues to Save Lives
  • ]]>
    Fri, 26 Jan 2018 00:00:00 -0500
    <![CDATA[AIDSinfo Updates Consumer Fact Sheets on Living with HIV]]>https://aidsinfo.nih.gov/e-news/archive/2018/1/12 The updated AIDSinfo consumer fact sheets provide important information for people living with HIV. Each fact sheet includes a summary of key points and links to additional information and resources.

    View the updated fact sheets:
    Visit infoSIDA to view the fact sheets in Spanish.
     
    ]]>
    Fri, 12 Jan 2018 00:00:00 -0500
    <![CDATA[ Scientific/Clinical Member Nominations Are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents with HIV]]>https://aidsinfo.nih.gov/e-news/archive/2018/1/12 The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise in HIV clinical research and clinical care, substance use and HIV, and transgender persons with HIV.

    Panel members critically evaluate new information and prepare guideline revisions. The candidates should be recognized experts in their areas of interest. The successful candidates will serve a 4-year term beginning April 2018, with potential for reappointment for an additional term.

    The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing and annually in a face-to-face meeting to review and critically evaluate emerging scientific data relating to antiretroviral therapy and revise the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. The latest guideline was published on October 17, 2017, and can be found at https://aidsinfo.nih.gov/.

    Panel members are not financially compensated for their time commitment.

    The nomination should include a curriculum vitae and a letter of interest or a letter of nomination (from a colleague) with specific reference to how the nominee would contribute to the work of the Panel, especially in the areas noted in bold above. Self-nomination is welcome. All supporting documents should be submitted to Alice Pau, Pharm.D., electronically (apau@niaid.nih.gov) by no later than January 19, 2018.
     
    ]]>
    Fri, 12 Jan 2018 00:00:00 -0500
    <![CDATA[ Recent HIV News from NIAID]]>https://aidsinfo.nih.gov/e-news/archive/2018/1/12
  • January 11, 2018: NIH Study Supports Use of Short-Term HIV Treatment Interruption in Clinical Trials 
  • ]]>
    Fri, 12 Jan 2018 00:00:00 -0500